# Safety and Durability of Sirolimus for Treatment of LAM

> **NCT02432560** · — · RECRUITING · sponsor: **University of Cincinnati** · enrollment: 600 (estimated)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02432560
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2015-03
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432560, "Safety and Durability of Sirolimus for Treatment of LAM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02432560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*